Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Prostatic Neoplasms 9Leukemia, Myeloid, Acute 9Endometrial Neoplasms 8Breast Neoplasms 7Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lung Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Multiple Myeloma 4Melanoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Colorectal Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Neuroblastoma 3Mouth Neoplasms 3Lymphoma, Follicular 3Leukemia 3Esophageal Neoplasms 3Brain Neoplasms 3

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × Observation × Clear all
NCT06743555 2026-04-28

SAVED LUNG

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 1 Not yet recruiting
14 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡